Login to Your Account

Personalized Medicine Stalls

Europe's Genetic Testing Labs Ignoring Biomarker IP

By Nuala Moran

Friday, August 19, 2011
LONDON – Another divide over patents is opening up between the U.S. and Europe as biomarkers are coming into more widespread use. Public sector genetic testing laboratories in Europe are ignoring intellectual property (IP) rights both because they do not think they are enforceable and because of a belief that such patents are not justified.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription